RadioGenes2: Modelling complex biomolecular interactions in radiated tumours: Towards understanding the genesis of therapeutic radioresistance. About 45% of bladder cancer patients require radiotherapy or surgery. Radiotherapy has a failure rate of ~50%. Surgery (bladder removal) diminishes quality of life considerably. Modelling complex gene interactions in radiated cancer cells will provide crucial knowledge on the molecular genesis of radiotherapy-resistance of tumours. Our findings will prov ....RadioGenes2: Modelling complex biomolecular interactions in radiated tumours: Towards understanding the genesis of therapeutic radioresistance. About 45% of bladder cancer patients require radiotherapy or surgery. Radiotherapy has a failure rate of ~50%. Surgery (bladder removal) diminishes quality of life considerably. Modelling complex gene interactions in radiated cancer cells will provide crucial knowledge on the molecular genesis of radiotherapy-resistance of tumours. Our findings will provide: (i) an accurate mathematical/computational model for diagnosing radiosensitivity; (ii) further insights to be applied in the pharmaceutical sector such as the discovery of novel molecular targets that have the potential to increase radiotherapy success ratios; (iii) a holistic modelling technique applicable to a larger diversity of tumours.Read moreRead less
Functionalised MMP Inhibitors as Radiodiagnostic, Radiotherapeutic, and Radiation-Sensitising Agents for Metastatic Cancer. Identifying and treating malignant cancers is one of the major challenges facing the scientific and medical communities. In order to minimise side effects that accompany most treatments of cancer it is necessary to find ways of targeting the therapy to tumours and away from healthy organs. A difference between tumours and healthy tissues is the amount of the proteins (calle ....Functionalised MMP Inhibitors as Radiodiagnostic, Radiotherapeutic, and Radiation-Sensitising Agents for Metastatic Cancer. Identifying and treating malignant cancers is one of the major challenges facing the scientific and medical communities. In order to minimise side effects that accompany most treatments of cancer it is necessary to find ways of targeting the therapy to tumours and away from healthy organs. A difference between tumours and healthy tissues is the amount of the proteins (called MMPs) that tumours use to break out of their surroundings, to break into and out of the blood system, and to establish new colonies of cancer cells or metastases. This difference also distinguishes the most aggressive cancers. The purpose of this project is to develop means of identifying and targeting cancers using molecules that bind to these MMP proteins.Read moreRead less